



GLOBAL TASK FORCE ON
CHOLERA CONTROL

LABORATORY WG ACHIEVEMENTS

Marie-Laure Quilici (Institut Pasteur)
21 May, 2024

1. BACKGROUND

THE GLOBAL ROADMAP FROM A LABORATORY PERSPECTIVE

Three strategic focus areas have been identified in The Global Roadmap for Ending cholera

Axis 1: Early detection and quick response to contain outbreaks at an early stage

Axis 2: Multisectoral approach to prevent cholera in hotspots (PAMI) in endemic countries

Axis 3: Effective mechanism of coordination for technical support, resource mobilisation, and partnership at the local and global level.

The Laboratory Working Group develops laboratory-specific approaches and also works jointly on specific topics with the Epi group as part of the Surveillance Working Group

SPECIFIC TASKS OF THE LABORATORY WORKING GROUP

- Provide tools for technical support of laboratories (forms, job aids, fact sheets, data sheets etc...)
- Support countries to map existing capacities, and link with epidemiological data to identify laboratory needs around PAMI.
- Identify needs and in particular mechanisms for provision of equipment/supplies and establish a link with donors
- Support the training of laboratory staff in testing and testing strategies to improve performance and speed
 - At central/reference lab level
 - At peripheral level (particularly around PAMI)
- Provide elements of quality assurance and progress assessment
- Establish links with and promote regional and sub-regional laboratory networks to improve preparedness and coordination.
- Explore opportunities for potential cross-fertilisation with other disease fields and promote the strengthening of bacteriology laboratories as a whole.

LABORATORY WORKING GROUP ACTIVITIES 2023-2024

Another busy year on many different fronts, and introduction of new activities


- Guidance and Tools
- New activities
 - Capacity assessment (field visits)
 - Implementation of initial training activities in the field
 - Development of support materials for training

2. ACHIEVEMENTS

LWG WORKPLAN 2023

Category / Thematic area	Activities (description)	2023										2024					Status
		May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May			
Guidance development	Environmental Surveillance Technical Note															V1 published	
	Minimum Standards for Lab Capacity															*activity postponed to 2025	
	General Technical Guidance for PCR															*activity postponed to 2025	
	Laboratory Testing Strategy																
Technical tools	AMR Fact sheet															Drafted, in design	
	Stool specimen collection															Drafting	
	Lab Referral Form															Drafted, in design	
	Lab Reporting Form															Drafted, in design	
	Form to Accompany Shipment of Isolates															Drafted, in design	
Lab Capacity Assessments	Finalize Capacity Assessment Toolkit															V1 drafted	
	Pilot in 4 countries															2 done, 2 in preparation	
Training of Lab Personnel	Develop training plan/ materials/checklists															Drafted, in design	
	Online training modules																
	Implement ToT in 4 priority countries															2 done, 2 in preparation	
Surv WG Subgroup activities	Updated surveillance guidelines															Finalizing	
Improving Cholera Diagnostics Initiative	RDT TPP Review															Finalized	
	TPP Development Mol. Diag.															Public consultation	
	Mol. Diag. Evaluation Protocol															Ongoing	

PUBLIC HEALTH SURVEILLANCE FOR CHOLERA GUIDANCE DOCUMENT 2024



A new review has been carried out from June to September 2023 by the EPI working group

- New epi-settings considered for **adaptive** surveillance
- New definitions, added or simplified
- Revised structure of the guidance

The Laboratory WG refined specific laboratory items:

- Improving the language used for the laboratory section
- Removing the SOP aspects, intended to be included in a specific document
- Checking that the testing recommendations were still appropriate
- Adding a section on laboratory capacity

Public health surveillance for cholera

Guidance Document
2024



English: <https://www.gtfcc.org/wp-content/uploads/2024/04/public-health-surveillance-for-cholera-guidance-document-2024.pdf>

French: ongoing

ASSESSMENT OF CHOLERA SURVEILLANCE – GUIDANCE DOCUMENT

Guidance document providing a method to assess compliance with the Surveillance Guidance

- 👉 Aims to assess the cholera surveillance strategies and the cholera surveillance system in the country and to identify critical gaps, areas of improvement, capacity to be maintained.
- 👉 To be performed as a self-assessment by countries at a minimum when NCP is developed.


From laboratory perspective

- 👉 Evaluation of laboratory capacities (reference laboratory capacity, capacity of the national laboratory system, decentralisation of laboratory surveillance)
- 👉 Evaluation of testing recommendations for early detection and monitoring of cholera outbreaks
- 👉 Based on the laboratory minimum capacities defined in this document



English: <https://www.gtfcc.org/wp-content/uploads/2024/05/gtfcc-assessment-of-cholera-surveillance-en.pdf>

French: ongoing



TOOLS: ANTIMICROBIAL SUSCEPTIBILITY TESTING

Fact-sheet V1



Laboratory Methods for antimicrobial susceptibility testing (AST) for *Vibrio cholerae*: points of particular attention

This document discusses a few critical points regarding the laboratory procedures for phenotypic antimicrobial susceptibility testing by diffusion methods, using antibiotic impregnated discs (Kirby-Bauer method) and test strips, as presented in Job Aid 'Antimicrobial susceptibility testing for treatment and control of cholera'. Other methods exist for this phenotypic detection, dilution methods including broth microdilution and agar dilution, but these are more expensive and difficult to implement therefore not generally recommended by the GTFCC.

Standard protocols for antimicrobial susceptibility testing are described in detail in the Antibiogram guidelines and references (CLSI¹, EUCAST², CASFM EUCAST³).

Safety Compliance. Testing of *Vibrio cholerae* and other potentially infectious specimen should always be performed in compliance with laboratory safety policies and procedures. Personal protective equipment (PPE) should be worn when handling potentially infectious materials. Always consult individual SDS (safety data sheet) forms for reagent specific information.

Quality Control Strains (QC). According to Antibiogram guidelines and references¹⁻³, QC strains should be included to monitor the AST system to ensure accurate and reproducible results and always be set up in parallel with test strains. Selection is based on what is needed to cover each drug being tested, see below. However other available laboratory strain carefully characterized and with known susceptibility to the antimicrobial agents tested can be used.

Azithromycin (MIC) *S. aureus* ATCC 29213
Erythromycin (diameter) *S. aureus* ATCC 29213
Pefloxacin (diameter) *E. coli* ATCC 25922
Ciprofloxacin (MIC) *E. coli* ATCC 25922
Tetracycline (diameter) *E. coli* ATCC 25922
Doxycycline (MIC) *E. coli* ATCC 25922

Quality and preparation of Medium. Mueller-Hinton agar medium is the only susceptibility test medium that has been validated by international guidelines¹⁻³. Commercially ready-to-use dehydrated Mueller-Hinton media are recommended. Agar should be poured into flat bottom glass or plastic petri dishes on a level pouring surface to a uniform depth of 4 mm ± 0.5 mm. **Greater or lesser depths affect the diffusion of antimicrobial agents and drug activity may be affected.**

Each new batch of medium should be tested for sterility, ability to support growth of the target pathogen, ability to produce appropriate antibiogram pattern with the control strain. Store the poured Petri dishes at 4-8°C according to the manufacturer's instruction. The agar surface must be dry before use but be careful not to dry out the agar.

Inoculum preparation. The inoculum must be realized using a **freshly sub-cultured strain** (16-18h at 35°C ± 2°C) on suitable non-selective media such as Mueller Hinton Agar, Brain Heart Infusion Agar or Trypticase Soy Agar, inoculated so as to have isolated colonies. Also streak the ATCC QC strains needed for disk diffusion testing and incubate in the same manner. Make a bacterial suspension in saline from **several isolated colonies** (to avoid selecting an atypical variant) to achieve a turbidity equivalent to that of the McFarland 0.5 standard. Adjust the density by adding either saline solution or bacteria.

Inoculating agar plates. Bacterial inoculum should ideally be used within 15 min of preparation but within 60 min at the latest. Dip a sterile cotton swab into the bacterial suspension and remove excess liquid by rotating the swab on the wall of the tube. If several agar plates are to be inoculated with the same inoculum, it is necessary to correctly reload the swab between each agar plate. Scratch the entire surface of the plate 3 times, rotating 60 degrees each time, ensuring that there are no gaps between streaks. **Discs or test-strips should be deposited within 15 min of inoculation.** If plates are left too long at laboratory temperature before discs or test-strips are deposited, the bacteria may start to grow, leading to a false decrease in the size of the inhibition zones.

1. CLSI (Clinical Laboratory Standards Institute) M7-A9: Performance Standards for Antimicrobial Susceptibility Testing - 9th Edition. CLSI, 2019. <https://www.clinical-lab-standards.org/standards-and-guidelines/products/m7-a9-performance-standards-for-antimicrobial-susceptibility-testing-9th-edition>
2. EUCAST (European Committee for Antimicrobial Susceptibility Testing) M10: Antimicrobial susceptibility testing of bacteria by disk diffusion. EUCAST, 2018. https://www.eucast.org/antimicrobial_testing/10_disk_diffusion
3. CASFM (Canadian Society for Antimicrobial Susceptibility Testing) EUCAST (European Committee for Antimicrobial Susceptibility Testing) M10: Antimicrobial susceptibility testing of bacteria by disk diffusion. CASFM, 2023. https://www.casfm-microbiologie.org/en/content/uploads/2023/06/CASFM2023_V1_0.pdf

V1.0 May 2024

Job-aid V3

Revised in line with new recommendations



Antimicrobial Susceptibility Testing for Treatment and Control of Cholera

OBJECTIVE: To provide instruction for determining in vitro susceptibility of *Vibrio cholerae* O1/O139

METHODS

- Agar disk diffusion method with antibiotic impregnated disks at predetermined concentrations.
- Measurement of minimum inhibitory concentration (MIC) by using test-strips impregnated with a gradient of predefined concentrations of antibiotics.

NOTE: Test strips are recommended for antibiotics for which no breakpoint is defined or when complementary tests are needed.
NOTE: Control strains should always be set up in parallel with test strains.

MATERIALS REQUIRED

- Mueller Hinton Agar (MHA) plates (4 mm ± 0.5mm deep)
- Sterile saline solution (0.85% or 0.9%) = test tubes of identical size for bacterial suspensions and the McFarland turbidity standard
- Sterile cotton tipped swabs
- Automatic disk dispenser or template with 5 or 6 disk spacing pattern and forceps
- Metric ruler (that can measure in mm)
- 0.5 McFarland turbidity standard
- Sheet of white paper with sharp black lines (can be prepared at home or printed out)
- Control strains: *Escherichia coli* ATCC25922
Staphylococcus aureus ATCC29213

Antibiotic to be tested and recommended method:

Initial screen test by disk diffusion Confirmation test by MIC measurement

- Erythromycin (EM) (15 mg)
- Rifampicin (RF) (5 µg)
- Polycaxacin (CP) (30 µg)
- Azithromycin (AZ)
- Ciprofloxacin (CIP)
- Doxycycline (DO)

AZ, CIP and DOX are the three selected antibiotics recommended for treatment of cholera according to GTFCC. <https://www.who.int/docs/default-source/antibiotic-use/antibiotic-use-in-the-treatment-of-cholera.pdf?ua=1>

*Store antibiotic disks and test-strips between -20°C and 8°C according to manufacturer's instructions.

*Check expiration date of antibiotic disks and test strips prior use.

PROCEDURE FOR DISK AND STRIP TESTING

- 1. Preparation of inoculum.** Prepare a bacterial suspension with a few well-isolated colonies from an overnight (18-24 hours at 35 ± 2°C) agar culture in sterile saline solution adjusted to 0.5 McFarland¹ by comparison to the standard.
NOTE: Ensure that the Standard is adjusted into a tube that is the same size as the plate used to prepare the test suspension.
Depending on an inoculum of approximately 1 to 2 x 10⁸ CFU/ml (turbidity ~0.5 to 0.7)
- 2. Inoculation of MHA.** Dip cotton swab in bacterial suspension, remove excess liquid by pressing the swab against the inside wall of the tube. *Stroke the entire surface of the plate 3 times, rotating 60 degrees each time. *Ensure the surface is completely dry before the next step.
- 3. Application of antibiotic disks.**
 - Not more than 15 minutes after swabbing.
 - Place the disks individually with an automatic disk dispenser or sterile forceps, gently pressing down onto the agar.
 - Do not move disks once deposited.
 - Replace lid, invert the plates and place in the incubator.

NOTE: Allow disks to reach ambient temperature before opening cartridge or container for storage.
- 4. Application of test-strips.**
 - Not more than 15 minutes after swabbing.
 - Place the strips on the agar according to the recommendations of the manufacturer.
 - Do not move strips once deposited.
 - Replace lid, invert the plates and place in the incubator.

NOTE: Test strips must be correctly stored in a dryer at 20°C. Allow strips that will be used to reach ambient temperature before placing on the agar.
- 5. Incubation:** 18 ± 2 hours at 35°C ± 2°C.
- 6. Reading:** After 18 ± 2 hours, observe the plate and measure the diameter (mm) of the inhibition ring. Read MIC value (µg/ml) at the intersection of the lower part of the ellipse-shaped growth inhibition area with the test-strip. If a MIC value is between two fold dilutions, always round up to the highest value.

INTERPRETATION OF RESULTS

Quality Control: If the control strain results are unexpected or out of range, any results on *V. cholerae* strains are invalid and the laboratory should investigate the source of error.

- Tetracycline screening test for doxycycline sensitivity. Strains sensitive to TC can be interpreted as sensitive to doxycycline. According to CASFM/EUCAST, if TC resistant, doxycycline must be tested individually by MIC measurement.
- Polycaxacin screening test for ciprofloxacin sensitivity testing.
- Erythromycin screening test for azithromycin sensitivity testing.

NOTE: MIC measurement by AZ and CIP is not required for case management but is recommended for epidemiological surveillance of strains.

INTERPRETATION: please refer to one of the following standards:
 CLSI: <https://doi.org/10.189/0730-0830-1016>, Table 20. *Vibrio* spp. (including *Vibrio cholerae*)
 EUCAST: https://www.eucast.org/antimicrobial_testing/10_disk_diffusion
 CASFM / EUCAST: https://www.casfm-microbiologie.org/en/content/uploads/2023/06/CASFM2023_V1_0.pdf

NOTE: The standards are reviewed on a regular basis, please check you are using an up-dated version.
 This document is intended for use by Reference Laboratories. Please keep update until testing is complete or in accordance with the laboratory sample retention policy.

© GTFCC, 2024. May 2024



English: <https://www.gtfcc.org/wp-content/uploads/2024/05/gtfcc-fact-sheet-laboratory-methods-for-ast-for-cholera-en.pdf>
 French: <https://www.gtfcc.org/wp-content/uploads/2024/05/gtfcc-fact-sheet-laboratory-methods-for-ast-for-cholera-fr.pdf>



English: <https://www.gtfcc.org/wp-content/uploads/2024/03/gtfcc-job-aid-antimicrobial-susceptibility-testing-for-treatment-and-control-of-cholera-en.pdf>
 French: <https://www.gtfcc.org/wp-content/uploads/2024/03/gtfcc-job-aid-antimicrobial-susceptibility-testing-for-treatment-and-control-of-cholera-fr.pdf>

TOOLS: JOB-AID ON RDT USE

- Images updated by a designer
- Slightly revised

Rapid Diagnostic Test (RDT) for cholera detection Quick Reference Guide – *For more detailed instructions please refer to the manufacturer's Package Insert*

GLOBAL TASK FORCE ON CHOLERA CONTROL

Indication of use

- RDTs are not used for individual diagnosis.
- RDTs are used as a tool for **early outbreak detection only** and once the outbreak is declared **for triaging the samples** to be sent to the laboratory.
- Perform RDT on fresh stool specimens and process within 2 hours of collection (or according to manufacturer specifications).

Before you start

- Check the expiry date. If expiry date has passed, use another kit.
- Read carefully the instructions for use in its entirety.
- Ensure the reagent bottle is intact and solution is not turbid or discoloured. Discard bottle if unsatisfactory.

At the end

- Place all waste in a double-lined plastic bag labelled "Biohazard."
- Record the test results in the patient's information record or registers.
- Keep samples under adequate conditions and send them to the laboratory for culture or PCR (see GTFCC packaging and shipping job aids).
- Report results accordingly.

1 Wear appropriate personal protective equipment. Put on the gloves. Use new gloves for each patient.

2 Open the cap of the sample processing vial or specimen collection tube. Label tube with patient identifier.

3 **Solid fecal specimens:** Collect the sufficient fecal specimens using the specimen collection swab. **Liquid fecal specimens:** Draw liquid fecal specimens up to the fill line using disposable dropper.

4 Tightly recap sample processing vial or collection tube and shake to mix contents.

5 Break or open the outer end of the cap (point away or cover with tissue to avoid splash). Dispense 4 drops of processed sample into labelled 5 ml test tube.

6 Carefully open test pouch. Discard if damaged, or if desiccant is missing or changed in color. Write patient's name on the dipstick or cassette.

7 **Dipstick:** Place the dipstick in the test tube with the arrows facing down. Confirm the end of the dipstick is submerged in the processed sample. **Cassette:** Hold the collection tube vertically and dispense 3 drops into specimen well "S".

8 **Dipstick: Wait 15-30 minutes.** Remove dipstick and read the result. **Cassette: Wait 15 minutes and read the results.**

As each RDT type, even from the same manufacturer, may have different positions for positive and control lines on the strip, please use the instructions provided with the specific RDT in use for correct interpretation.

Example → The control line **MUST** appear for all valid results. If it does not appear, the result is considered invalid and the specimen should be retested using a new test kit.

V2.0 April 2024



English: <https://www.gtfcc.org/wp-content/uploads/2022/01/gtfcc-job-aid-rapid-diagnostic-test-for-cholera-detection-en-1.pdf>


French: <https://www.gtfcc.org/wp-content/uploads/2023/07/gtfcc-job-aid-rapid-diagnostic-test-for-cholera-detection-fr-1.pdf>

TPP FOR A RAPID DIAGNOSTIC TEST FOR SURVEILLANCE OF CHOLERA OUTBREAKS

Development of this TPP document coordinated by FIND with a financial support by Gavi
 TPP development leadership team (5 persons)
 TPP development focus group (13 persons)
 Public consultation review and comments involving members of the Lab Working group
 Level of agreement averaging 95%

- TPP for cholera RDTs first published in 2017
- Need to update the TPP due to some criteria too stringents and advances in the field

CHARACTERISTIC	MINIMAL	PREFERRED
Clinical sensitivity ¹	≥ 90% for each assay target ²	≥ 95% for each assay target ³
Clinical specificity ¹	≥ 85% for each assay target ²	≥ 95% for each assay target ³



<https://www.gtfcc.org/resources/target-product-profile-for-a-rapid-diagnostic-test-for-surveillance-of-cholera-outbreaks/>

3. IN PROGRESS

DOCUMENTATION TO ACCOMPANY SHIPMENT OF ISOLATES

GTFC Laboratory Referral Form for Cholera Suspected Case

The referring health worker is to complete this form and send a copy to the laboratory with the specimen (one form per specimen case).
Please attach a copy of the Admission and Triage Form (Appendix 12 of the Cholera Outbreak Manual).
For specific instructions for packaging and transportation please refer to Specimen Packaging and Domestic Transportation for Laboratory Confirmation of Vibrio cholerae O1/O139.

Request made by
Name/Address of laboratory (or stamp) _____
Name of laboratory director/contact person _____
Phone _____ E-mail _____
Signature _____

Request made for
 Laboratory identification of Cholera Antimicrobial Susceptibility Testing Other, specify _____

Specimen
Specimen ID: _____ Date of specimen collection: ____/____/____
Location specimen collected: _____
Type of specimen collected: Stool Rectal swab Other, specify: _____
Blood observed in stool: Yes No
Appearance of specimen: Formed Soft Watery Bloody/mucous
Conditioning of stool sample: Stool in container (no added reagents) in Cary Blair in Alkaline Peptone Water (APW) on filter paper
 other, specify: _____
Date specimen sent to referral laboratory: ____/____/____
If date of specimen collection and date specimen sent are different, how was the specimen stored (media, temperature)? _____
Was an RDT performed on the same specimen? No Yes, specify: Enriched RDT Direct RDT
Name of RDT kit used: _____
Result: Positive Negative Indeterminate

Page 1 of 2 (Include ID: _____)

GTFC Laboratory Reporting Form for Suspected Cholera Case

The laboratory is to complete this form and send a copy to the relevant health authorities and requesting clinician.
The type of results reported in this form are mostly based on the methods recommended by the GTFCC and that match the contents of the WHO cholera laboratory kits. Other tests and results may be reported.
For more information on testing for cholera refer to GTFCC Job Aid: Rapid Diagnostic Test (RDT) for cholera detection, Isolation and Presumptive Identification of Vibrio cholerae O1/O139 from fecal specimens, Antimicrobial Susceptibility Testing for Treatment and Control of Cholera.

Report made by
Name/Address of laboratory (or stamp) _____
Name of laboratory director/contact person _____
Phone _____ E-mail _____
Signature _____

Patient and specimen information
Patient full name: _____ Patient ID: _____ Sex: Male Female
Age: ____ Years/ ____ Months/ ____ Days or date of birth: ____/____/____
Date of onset of illness: ____/____/____ Specimen ID: _____
Date that sample was collected: ____/____/____ Date of receipt of specimen at laboratory: ____/____/____
Specimen condition for testing: Adequate Not adequate, specify _____

Laboratory results

RDT
Performed in lab: No Yes, specify: Enriched RDT Direct RDT
Name of kit used: ____/____/____
Date test performed: ____/____/____
Result: Positive Negative Indeterminate

Culture
 on TCBS: Directly from sample: Yes No
After enrichment in Alkaline Peptone Water (APW): Yes No
 on Non Selective Agar (NSA):
Directly from sample: Yes No
After enrichment in APW: Yes No
Others, specify: ____/____/____
Date test performed: ____/____/____
Results:
 Growth on TCBS, specify color and aspect of colonies of growth: _____
 Growth on NSA

Cholerae test
Performed: Yes No
Date test performed: ____/____/____
Result: Positive Negative

Page 1 of 2 (Include ID: _____)

GTFC Isolate submission form

The submitting laboratory should complete a form for each individual isolate sent to a recipient laboratory.
This form is to be filled out and accompany any shipment of isolates to a secondary/referral laboratory for further testing (such as AST or sequencing) or even for confirmatory purposes. The submitting laboratory should complete a form for each individual isolate sent to a recipient laboratory.
Isolates must be labeled with corresponding documentation (Laboratory Referral Form for Cholera Suspected Case and/or In-line list). Include any results of tests that may have already been performed, such as RDT results. **IMPORTANT: Inform the receiving lab before sending the specimen.**
For more specific instructions for packaging and transportation please refer to Strain Conditioning for International Transportation of Vibrio cholerae O1/O139 Job Aid.¹

Request made by
Name/Address of Laboratory (or stamp) _____
Name of laboratory director/contact person _____
Phone _____ E-mail _____
Signature _____

Tests requested:
 Confirmatory diagnostics: Specify: Identification, serotyping Toxin testing Antimicrobial Susceptibility Testing (AST)
 Genomic sequencing (NGS) Other, specify _____

Isolate
Isolate ID: _____
Conditioning of isolate: culture inoculated on non-selective medium (agar slant), specify medium?
 culture inoculated on stock culture agar, specify type of agar?
 culture on wet filter paper?
 other, specify: _____
Date of primary specimen collection: ____/____/____
Location initial specimen collected: Province/Region _____ District _____ Town/Village _____

Patient
Patient ID: _____ Sex: Male Female
Age: ____ Years/ ____ Months/ ____ Days or Date of birth: ____/____/____
Date of onset of illness: ____/____/____
Suspected location of contamination: Province/Region _____ District _____ Town/Village _____
Patient outcome: Hospitalized Discharged Deceased Self-discharged Refered, specify _____ Unknown
Did the patient fit the clinical suspect case definition for cholera? Yes No
Is there a notion of cluster of cases? No Yes, specify _____
Relevant travel history: _____

Page 1 of 2 (Include ID: _____)

- **Lab referral form:** for health care workers to fill and send to laboratories with samples collected from suspect cases. Minimal data for laboratories to perform tests and interpret test results.

- **Lab reporting form:** for laboratories to report results back to clinicians and/or public health authorities. To contain minimal data to be further included in National database.

- **Isolate submission form:** for laboratories to accompany any shipment of isolates to a secondary/referral laboratory for further testing (such as AST or sequencing) or even for confirmatory purposes.

SUPPORTS FOR TRAINING : STANDARDISED TRAINING MATERIALS

Training package 1 for field staff, Module 1 “Introduction to Cholera and Testing for Cholera”

Training package 1 for field staff, Module 2 “Sample collection, Preparation and Transport for Cholera”

Training package 1 for field staff, Module 3 “Cholera Rapid Diagnostic Tests”



COURSE OUTLINE

MODULE 1

Introduction to cholera and testing for cholera

MODULE 2

Sample collection, preparation and transport for cholera

MODULE 3

Cholera rapid diagnostic tests (RDTs)



GLOBAL TASK FORCE ON CHOLERA CONTROL

GTFCC recommendations

SAMPLE COLLECTION, PREPARATION AND TRANSPORT FOR CHOLERA

V1.0 May 2024



GLOBAL TASK FORCE ON CHOLERA CONTROL

GTFCC recommendations

CHOLERA RAPID DIAGNOSTIC TESTS (RDTs)

V1.0 May 2024

LABORATORY CAPACITY ASSESSMENT TOOLS

- A necessary tool to help identify the needs of laboratories and the actions to be developed.
- First version re-developed in 2023
- Used for field evaluation in two countries in 2023 and 2024, DRC and Cameroon
- Their use in the field has highlighted a number of difficulties
- A new version is currently developed by a new consultant.

TPP FOR MOLECULAR DIAGNOSTIC

- Document under development on the same principle as TPP for RDTs
- Conducted by FIND funded by GAVI
 - Effective surveillance requires diagnostic testing at all levels of the healthcare system, from communities and primary care to reference laboratories in public health institutions
 - Positive RDT results require confirmation by either culture or molecular methods
 - Molecular diagnostic tests can improve the quality and availability of laboratory data, easy-to-use, fit-for-purpose, well-performing, validated diagnostic tests are needed

JOB-AID STOOL SPECIMEN COLLECTION

- A focal point had been identified last year
- No draft document was provided but some comments and instructions were discussed
- This work is still ongoing

4. INTRODUCTION OF NEW ACTIVITIES

TRAINING

- Initiated in 2023 and funded by CDC and WHO IMST
- Includes the development of training materials and training of trainers in countries
- Implemented this year in an emergency context to support three countries: South Sudan, Somalia and Comoros Islands.

LAB CAPACITY ASSESSMENT

- Re-initiated in 2023.
- Funded by CDC
- Included the development of capacity assessment tools and the piloting of assessment in 4 priority countries
- First set of tools developed
- Two countries were visited

5. NEXT STEPS

- Continuation of ongoing activities, finalization of documents
- Large diffusion of documents and guidelines produced
- Definition of a new working plan for the coming year based on discussions and exchanges at this meeting
- Call for more Focus people to draft documents



GLOBAL TASK FORCE ON
CHOLERA CONTROL

THANK YOU |